Emerging Therapies for PBC, NASH, ESLD and HCC

2018 An Evidence-Based Seminar Focused on Chronic Liver Diseases

Don’t Miss Out On This National Program Coming To A City Near You!

PROGRAM HIGHLIGHTS
- New content based on the latest clinical guidelines and outcomes trials developed by national experts
- Strong patient-focused educational sessions using evidence-based studies from the latest AASLD, EASL and DDW programs
- Interactive format that includes practical patient case review, small group discussion and the use of Audience Response Technology to gauge opinion and build consensus
- Convenient local venues and affordable registration fees
- Teams of local experts, comprised of physicians and advanced practice providers, providing an interdisciplinary team approach to treatment.
- Participants can receive up to 6.0 AMA PRA Category 1 Credits™ or up to 7.1 nursing education credits

WHO SHOULD ATTEND
This program is especially suited for Hepatologists, Gastroenterologists, Internists, and Family Physicians, as well as related advanced practice providers, clinical pharmacists and nurse specialists.

Primary Biliary Cholangitis (PBC) is an old disease but one that is experiencing some major changes. A new treatment, Obeticholic Acid (OCA), the first new drug for the disease in 20 years, is expected to be a breakthrough for patients who have had an incomplete response to Ursodiol (URSO).

Non-Alcoholic Steatohepatitis (NASH) is an epidemic in the US and is expected to be the major cause of cirrhosis in the coming decades as chronic Hepatitis C quickly wanes. There are many unmet needs associated with NASH including simple biomarkers to help diagnose it and follow experimental therapies. Clinical experts will provide a thorough review of non-invasive diagnostic testing and discuss several exciting new therapies being developed.

End Stage Liver Disease (ESLD) is expected to continue to grow in prevalence largely due to the burden of chronic viral hepatitis that exists in our population. As these patients age, a larger number will develop decompensation events such as variceal bleeding, hepatic encephalopathy, hyponatremia and renal failure.

Hepatocellular Carcinoma (HCC) is the most common form of liver cancer and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. New research is yielding some promising therapies.
EDUCATIONAL OBJECTIVES
After attending this activity, participants should be able to:
> Speak to new treatments for liver disorders using evidence-based literature.
> Review the current therapies and new treatment options for PBC.
> Evaluate diagnostic tests for PBC, NASH and HCC that are in daily use soon, including newer non-invasive tools and procedures.
> Discuss the therapeutic and management options for HCC: Ablation, TACE and Chemotherapies.
> Identify the multiple causes for renal insufficiency in patients with ESLD including diuretic overdose, GI bleeding, systemic infection, hepatic decompensation, and hepatorenal syndromes type 1 and 2.
> Discover why immunotherapy is the new Mechanism of Action for HCC.
> Consider the benefits of therapeutic and lifestyle approaches to managing NAFLD and NASH patients.
> Follow the guidelines for diagnosis and management of ascites in patients with ESLD including diuretics, therapeutic paracentesis, and transjugular intrahepatic portosystemic shunt (TIPS).
> Solve detailed clinical studies based on the lessons presented in the seminar.

COURSE DIRECTORS
Paul Pockros, MD, FACG
Director, Liver Disease Center, Scripps Clinic
Director, Clinical Research
Scripps Translational Science Institute

Catherine Ferrante, MD,
Medical Director for Liver Transplantation
Director, Center of Excellence for HCC
Scripps Center for Organ and Cell Transplantation

Registration Information

<table>
<thead>
<tr>
<th>Early Registration</th>
<th>Regular Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians and Clinical Pharmacists</td>
<td>$95</td>
</tr>
<tr>
<td>Nurses, Nurse Practitioners and PAs</td>
<td>$70</td>
</tr>
<tr>
<td>Medical Residents &amp; Fellows</td>
<td>$60</td>
</tr>
</tbody>
</table>

Or call: University of Louisville CME & PD (502) 852-5329

Early Registration ends Tuesday prior to program date.
Regular Registration begins Wednesday prior to through program date.

Cancellation Policy – Requests for cancellation must be submitted to cmepd@louisville.edu at least seven (7) days prior to the program. Such requests will receive a full refund less a $20 processing fee.